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Abstract
Background: Intralesional triamcinolone acetonide (TAC) injections are often used as the first alternative for
treating keloid scarring. The long-term outcome of this treatment is unclear. Also, undesirable local side effects have
been recognized in clinical work and literature but they have been labelled as harmless and rare.
Methods: We documented the long-term outcome of intralesional TAC injections in the treatment of keloid scars
in Tampere University Hospital. The main objectives were to investigate the remission rate and the occurrence of
local side effects. We assessed 105 patients (46 women, 59 men) with 138 TAC treated keloid scars at the
outpatient clinic. The keloids were photographed and assessed with Patient and Observer Scar Assessment Scale
(POSAS).
Results: Of the 138 keloids, 90 (65%) were clinically in remission. Local side effects, including atrophy of the skin
or the subdermal fat, telangiectasia and cortisone traces, occurred in 55% of the cases. The number of injections did
not correlate with remission rate or the occurrence of local side effect. ROC curve analysis showed that surface area
>620 mm2 was a prognostic factor for not responding to TAC treatment.
Conclusion: According to this study, intralesional TAC injections seem to be effective in the treatment of small
keloids but not in larger than 620 mm2. Local side effects were more frequent than previously reported and occurred
even after just 1 injection. The side effects seem to be permanent in nature.
Keywords: Steroid injection; Triamcinolone acetonide; Keloid;
Steroid sensitivity; Hypertophic scars
Introduction
Keloid scars may develop following any trauma to the skin. The size
of the keloid is often disproportional to the size of the original trauma.
By definition, keloids are benign locally aggressive dermal fibro
proliferative tumours that grow beyond the boundaries of the original
wound [1,2]. The etiopathogenesis of keloid scarring has remained
poorly understood to date [2-5]. In addition to pain and itching,
keloids also cause functional and aesthetic impairment. Left untreated,
they may cause substantial long-term morbidity and emotional stress
[2,6-8]. It has been estimated that in the year 2000, 11 million people
were affected by keloids in the developed world alone [2].
Keloid management can be difficult and frustrating for the patient
as well as the clinician. There is no clear consensus on optimal keloid
treatment. Intralesionally injected steroids, especially triamcinolone
acetate (TAC), are commonly used as a first-line treatment. As early as
in the 1960s, authors reported curative results in up to 80% of the cases
[9-12]. Other, more recent studies suggest recurrence rates between 9%
and 50% with this line of treatment [13-17]. Alternative treatment
options include surgery followed by radiotherapy, and other injectable
substances, such as 5-fluorouracil, bleomycin and verapamil [18].
It has been stated, that some keloids do not respond to TAC
injections, these cases are considered steroid resistant [19,20]. There is
no consensus or clear indicator to detect steroid sensitive cases [19].
Systemic effects of steroids in keloid treatment are rare, but some
cases of Cushing syndrome have been reported, especially in children
[21-23].
However, there are known local side effects related to the TAC
injections, such as atrophy of the skin and the subcutaneous tissue;
telangiectasia; and pigmentation changes [7,18,24]. It has previously
been reported that although these effects may occur frequently, they
are usually resolved without intervention [14,18,25]. In our experience,
these effects tend to be longstanding and sometimes permanent,
sometimes needing surgical treatment.
The main objective of this study was to critically evaluate the long-
term outcome and adverse effects of keloid treatment with TAC
injections.
Patients and Methods
Initially, 270 invitation letters were sent to patients with diagnoses of
keloid scars in their medical records; 127 patients visited the outpatient
policlinic. 105 patients were diagnosed of having one or more actual
keloids (46 females and 59 males). This resulted in 138 keloid scars that
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had been treated with TAC injections in Tampere University Hospital
1996 and 2014.
The keloids were assessed with a validated scar scale, Patient and
Observer Scar Assessment Scale (POSAS) and a spectrocutometry
camera, as used in previous studies [26,27]. Both the patient and the
observer filled the POSAS form during visiting the outpatient clinic.
The POSAS scale consists of 6 items for the patient and the observer,
ranging from 1 to 10, giving an overall score of 6 to 60. In this study a
single observer assessed all the scars. The site and size of the keloids,
their etiology, received TAC injections, other treatment, subjective and
objective adverse effects and the remission rate were documented. Any
scar that was raised above the level of the surrounding skin and/or had
symptoms relating to an active keloid (itching, pain) was defined as a
recurrence.
Approval of the local ethics committee was obtained for the study.
The statistical assessment was carried out by a biostatistician. Statistical
analysis were performed with SPSS version 21.0 software (SPSS Inc.,
Chicago,IL). Categorical variables were analyzed by the χ2 – test.
Keloid area and remission analysis were performed using ROC-
analysis. P-value less than 0.05 were considered statistically significant.
Results
The mean age of the patients was 41.5 years (range: 18-82). The
most common anatomic site was the thoracic region (37%). The three
most common etiologies were surgery (46%), acne scars (25%), and
traumatic wounds (9.8%). The mean follow-up time was 4.27 ± 3.78
years. 65% of the TAC treated keloids were in remission at the time of
evaluation. However, when the size of the keloid was measured, 82% of
the keloids not in remission were larger than 620 mm2. This
mathematical cut point was achieved using ROC analysis.
Number of TAC injections 1 (n=25) 2-3 (n=68) ≥ 4 (n=45) P
Remission rate 76% 69% 52% 0.092*
Local side effects     
Skin atrophy 56% 58% 43% 0.288*
Telangiectasia 36% 31% 30% 0.911*
TAC traces 44% 48% 41% 0.784*
*Pearson Chi-Square test.
Remission rates and local side effects in keloids receiving 1, 2-3 or ≥ 4 TAC
injections. There was no correlation between the number of injections and
remission rate or local side effect.
Table 1: Number of TAC injections: remission rate and local side
effects after TAC intralesional treatment.
The mean treatment rate was 3.0 injections (range 1-10). However,
multiple injections did not lead to better results (Figure 1). The least
recurrences occurred in the group with only 1 injection, although this
was not statistically significant (Table 1).
Figure 1: Number of TAC injections and POSAS scores: multiple
injections did not lead to better results according to POSAS score.
There were local adverse effects in 55% of the keloids. There was no
correlation between the number of injections and the adverse effects
(Table 1). However, the difference between groups (local side effects
and non-side effects) wasn´t statistically significant.
Five patients required surgery due to local adverse effects (Figures 2
and 3).
Figure 2: Severe cosmetic problem and risk of skin breakdown
without recurrence. The patient had received 3 TAC injection.
Figure 3: Recurrent keloid growth around TAC treated area above
the acromion. Ulceration, skin thinning, telangiectasia and TAC
traces after 2 TAC injections. The patient underwent excision and
postoperative radiotherapy and is in remission after 1 year.
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Discussion
TAC injections affect keloid growth in several ways. They inhibit the
proliferation of fibroblasts and encourage scar regression. They also
inhibit collagen synthesis and reduce excessive scarring [19,28].
Corticosteroids, used intralesionally, decrease inflammation and
increase vasoconstriction in the scar tissue [6,7,29].
According to several publications, intralesional TAC treatment is a
standard first-line treatment modality in keloid scars [18,19,30,31]. It
has also been the most common treatment option in our hospital.
Hollander first reported the use and efficacy of intralesional TAC
injections in keloid treatment in 1961 [9]. Later, Griffith and Vallis
reported curative results and improvement in appearance after TAC
injections [10,12,32]. These trials showed symptom relief in up to 80%
of the cases [18]. In our study, the overall remission rate (65%) was
somewhat lower than in previous studies. Muneuchi et al. also
reported less favorable results than the previous studies; there was
improvement in subjective symptoms in 82% of patients, but
objectively the results were good or better in only 39% of the cases
[30].
An interesting finding in our study was that a surface area larger
than 620 mm2 was a prognostic factor for not responding to TAC
treatment. This would indicate keloids 2 x 3 cm or larger. Previous
authors have not investigated the size of the keloid when reporting
recurrence rates. Larrabee et al. estimate that roughly 50% of keloids
might be “cortisone resistant” [20]. It is reasonable to assume, that the
recurring, larger keloids had grown faster and were thus more
aggressive than the minor keloids that responded well to treatment.
Although this is not sufficient evidence to suggest that major keloids
do not respond to TAC injections, it warrants further investigation to
possibly avoid unnecessary, ineffective treatments.
We found that 55% of keloids treated with TAC had long-term local
adverse effects. Due to the long follow-up time (4.27 ± 3.78 years) in
our study, it is safe to say that a large number of these side effects are
permanent in nature. This finding is in contrast with previous studies
that have suggested significantly lower complication rates. Davidson et
al. reported local TAC complications in 15%, and Sadheginia et al. did
not detect any visible side effects in their group of 20 patients, who
were treated with TAC injections [33,34]. Furthermore, the number of
injections was lower in our patients. Muneuchi et al. used 20-30
injections over 3-5 years, but reported only few local side effects. The
concentration of TAC and the injection technique reported in their
study did not differ from the technique generally used by professionals
treating keloids [30].
Muneuchi et al., Sadheginia et al., and Davidsonet al. did not report
systemic complications or local adverse effects which needed further
treatment [30,33,34]. We recorded 5 patients, who were operated on
due to local side effects from TAC injections, but no systemic side
effects in our follow-up.
A further finding in our study was that increasing the number of
TAC injections did not yield better long-term results. On the contrary,
patients treated with less than 4 injections had better results compared
to patients receiving 4 or more injections. This finding may support the
suggestion made by Ud-Din et al. who state that a certain number of
keloids are less affected by cortisone treatment and thus exceeding the
number of treatments does not improve the outcome [19]. The
mechanism behind this is unclear and requires further investigation.
It is also worth noting, that there was no correlation between local
adverse effects and the number of injections in our study.
The weakness of this study was its retrospective nature, which may
cause selection bias. Some patients with good results may not answer
to the letter that was sent to them. The response rate was 47%. Since
the exact amount of TAC used in each treatment session was not
recorded in all the patients, we could not draw clear conclusions on
whether the side effects are related to injection technique, type of
steroid or the amount of injected steroid per cm2. However, the
material represents the current shape of treatment in our institution
following the current guidelines that the keloid patients receive and
their long-term results. It also supports the previous finding that some
keloids do not respond to cortisone treatment, and the size of the
keloid may be used as an indicator when planning treatment.
Conclusions
According to this study, it seems that while intralesional TAC
injections are not quite as effective as reported in previous studies they
still offer curative results especially in minor keloids, also in the long-
term. However, local adverse effects are common and may occur even
after a single treatment. These complications are not expected to
diminish and may, in the worst case, require further treatment. The
patient must be advised about this before the treatment, especially
when being treated for minor keloids with minimal symptoms.
Also, a higher number of injections did not lead to a better outcome
in terms of the recurrence rate. Therefore, it is advisable to limit the
injections to 4 or less and, in cases where there is no significant
improvement, to consider other lines of treatment instead.
Acknowledgment
This study was supported by Orion Pharma Research Fund and
Competitive State Research Financing of the Expert Responsibility area
of Tampere University Hospital, Grant 9R025. We would like to thank
Mrs Elina Adams for the language revision.
References
1. Robles DT, Berg DM (2007) Abnormal wound healing: keloids. Clin
Dermatol 25: 26-32.
2. Shih B, Garside E, McGrouther DA, Bayat A (2010) Molecular dissection
of abnormal wound healing processes resulting in keloid disease. Wound
Repair & Regeneration 18: 139-153.
3. Halim AS, Emami A, Salahshourifar I, Kannan TP (2012) Keloid scarring:
understanding the genetic basis, advances, and prospects. Archives of
Plastic Surgery 39: 184-189.
4. Brown JJ, Bayat A (2009) Genetic susceptibility to raised dermal scarring.
British Journal of Dermatology 161: 8-18.
5. Köse O, Waseem A (2008) Keloids and Hypertrophic Scars: Are They Two
Different Sides of the same coin? Dermatologic Surgery 34: 336-346.
6. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG (2011)
Hypertrophic Scarring and Keloids: Pathomechanisms and Current and
Emerging Treatment Strategies. Mol Med 17: 113-125.
7. Chike-Ob CJ, Cole PD, Brisset AE (2009) Keloids: Pathogenesis, Clinical
Features, and Managment. Semin Plast Surg 23: 178-184.
8. Davis SA, Feldman SR, McMichael AJ (2013) Management of keloids in
the United States, 1990-2009: an analysis of the National Ambulatory
Medical Care Survey. Dermatologic Surgery 39: 988-994.
9. Hollander A (1961) Intralesional injections of triamcinoloneacetonide: A
therapy for dermatomes. Antibiot Med Clin Ther 8.
Citation: Hietanen K, Välisuo P, Kuokkanen H, Kaartinen I (2016) Long-Term Results of Intralesional Triamcinolone Acetonide Injections in
Keloid Treatment. J Clin Trials 6: 278. doi:10.4172/2167-0870.1000278
Page 3 of 4
J Clin Trials, an open access journal
ISSN:2167-0870
Volume 6 • Issue 4 • 1000278
10. Griffith BH (1966) The treatment of keloids with triamcinolone
acetonide. Plast Reconstr Surg 38: 202-208.
11. Ketchum LD, Robinson DW, Masters FW (1971) Follow-up on treatment
of hypertrophic scars and keloids with triamcinolone. Plast Reconstr Surg
48: 256-259.
12. Vallis CP (1967) Intralesional injection of keloids and hypertrophic scars
with the Dermo-Jet. Plast Reconstr Surg 40: 255-262.
13. Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, et al. (2002)
International clinical recommendations on scar management. Plast
Reconstr Surg 110: 560-571.
14. Darzi MA, Chowdri NA, Kaul SK, Khan M (1992) Evaluation of various
methods of treating keloids and hypertrophic scars: A 10-year follow-up
study. Br J Plast Surg 45: 374-379.
15. Tang YW (1992) Intra and postoperative steroid injections for keloids
and hypertrophic scars. Br J Plast Surg 45: 371-373.
16. Kiil J (1977) Keloids treated with topical injections of triamcinolone
acetonide (kenalog). Immediate and long-term results. Scand J Plast
Reconstr Surg 11: 169-172.
17. Boyadjiev C, Popchristova E, Mazgalova J (1995) Histomorphologic
changes in keloids treated with Kenacort. J Trauma 38: 299-302.
18. AlAttar A, Mess S, Thomassen J, Kauffman C, Davison SP (2006) Keloid
Pathogenesis and Treatment. Plastic & Reconstructive Surgery 117:
286-300.
19. Ud-Din S, Bowring A, Derbyshire B, Morris J, Bayat A (2013)
Identification of steroid sensitive responders versus non-responders in
the treatment of keloid disease. Arch Dermatol Res 305: 423-432.
20. Larrabee WF, East CA, Jaffe HS (1990) Intralesional interferon gamma
treatment for keloids and hypertrophic scars. Arch Otolaryngol Head
Neck Surg 116: 1159-1162.
21. Ritota PC, Lo AK (1996) Cushing´s syndrome in postburn children
following intralesional triamcinolone injection. Ann Plast Surg 36.
22. Finken MJ, Mul D (2010) Cushing's syndrome and adrenal insufficiency
after intradermal triamcinolone acetonide for keloid scars. Eur J Pediatr
169: 1147-1149.
23. Fredman R, Tenenhaus M (2013) Cushing's syndrome after intralesional
triamcinolone acetonide: a systematic review of the literature and
multinational survey. Burns 39: 549-557.
24. Ogawa RM (2010) The Most Current Algorithms for the Treatment and
Prevention of Hypertrophic Scars and Keloids. Plastic & Reconstructive
Surgery 125: 557-568.
25. Friedman SJ, Butler DF, Pittelkow MR (1988) Perilesional linear atrophy
and hypopigmentation after intralesional corticosteroid therapy: Report
of two cases and review of the literature. J Am Acad Dermatol 19:
537-541.
26. Kaartinen IS, Valisuo PO, Bochko V, Alander JT, Kuokkanen HO (2011)
How to assess scar hypertrophy--a comparison of subjective scales and
Spectrocutometry: a new objective method. Wound Repair Regen 19:
316-323.
27. Kaartinen IS, Valisuo PO, Alander JT, Kuokkanen HO (2011) Objective
scar assessment--a new method using standardized digital imaging and
spectral modeling. Burns 37: 74-81.
28. Wu WS, Wang FS, Yang KD,  Huang CC, Kuo YR (2006) Dexamethasone
induction of keloid regression through effective supression of VEGF
expression and keloid fibroblast proliferation. J Invest Dermatol 126:
1264-1271.
29. Butler PD, Longaker MT, Yang GP (2008) Current Progress in Keloid
Research and Treatment. J Am Coll Surg 206: 731-741.
30. Muneuchi G, Suzuki S, Onodera M, Ito O, Hata Y, et al. (2006) Long-term
outcome of intralesional injection of triamcinolone acetonide for the
treatment of keloid scars in Asian patients. Scand J Plast Reconstr Surg
Hand Surg 40: 111-116.
31. Ledon JA, Savas J, Franca K, Chacon A, Nouri K (2013) Intralesional
Treatment for Keloids and Hypertrophic Scars: A Review. Dermatologic
Surgery 39: 1745-1757.
32. Griffith BH, Monroe CW, McKinney P (1970) A follow-up study on the
treatment of keloids with triamicinolone acetonide. Plast Reconstr Surg
46: 145-150.
33. Sadeghinia A, Sadeghinia S (2012) Comparison of the efficacy of
intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the
treatment of keloids. Dermatologic Surgery 38: 104-109.
34. Davison SP, Dayan JH, Clemens MW, Sonni S, Wang A, et al. (2009)
Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment
of keloids. Aesthet Surg J 29: 40-46.
 
Citation: Hietanen K, Välisuo P, Kuokkanen H, Kaartinen I (2016) Long-Term Results of Intralesional Triamcinolone Acetonide Injections in
Keloid Treatment. J Clin Trials 6: 278. doi:10.4172/2167-0870.1000278
Page 4 of 4
J Clin Trials, an open access journal
ISSN:2167-0870
Volume 6 • Issue 4 • 1000278
